Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review

Cardiocerebrovascular diseases (CVDs) are the leading cause of death worldwide, consuming huge healthcare budget. For CVD patients, the prompt assessment and appropriate administration is the crux to save life and improve prognosis. Thrombolytic therapy, as a non-invasive approach to achieve recanal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kexin, Jiang, Yao, Zeng, Hesong, Zhu, Hongling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476453/
https://www.ncbi.nlm.nih.gov/pubmed/37667349
http://dx.doi.org/10.1186/s12959-023-00532-0
_version_ 1785100935943421952
author Zhang, Kexin
Jiang, Yao
Zeng, Hesong
Zhu, Hongling
author_facet Zhang, Kexin
Jiang, Yao
Zeng, Hesong
Zhu, Hongling
author_sort Zhang, Kexin
collection PubMed
description Cardiocerebrovascular diseases (CVDs) are the leading cause of death worldwide, consuming huge healthcare budget. For CVD patients, the prompt assessment and appropriate administration is the crux to save life and improve prognosis. Thrombolytic therapy, as a non-invasive approach to achieve recanalization, is the basic component of CVD treatment. Still, there are risks that limits its application. The objective of this review is to give an introduction on the utilization of thrombolytic therapy in cardiocerebrovascular blockage diseases, including coronary heart disease and ischemic stroke, and to review the development in risk assessment of thrombolytic therapy, comparing the performance of traditional scales and novel artificial intelligence-based risk assessment models. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00532-0.
format Online
Article
Text
id pubmed-10476453
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104764532023-09-05 Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review Zhang, Kexin Jiang, Yao Zeng, Hesong Zhu, Hongling Thromb J Research Cardiocerebrovascular diseases (CVDs) are the leading cause of death worldwide, consuming huge healthcare budget. For CVD patients, the prompt assessment and appropriate administration is the crux to save life and improve prognosis. Thrombolytic therapy, as a non-invasive approach to achieve recanalization, is the basic component of CVD treatment. Still, there are risks that limits its application. The objective of this review is to give an introduction on the utilization of thrombolytic therapy in cardiocerebrovascular blockage diseases, including coronary heart disease and ischemic stroke, and to review the development in risk assessment of thrombolytic therapy, comparing the performance of traditional scales and novel artificial intelligence-based risk assessment models. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00532-0. BioMed Central 2023-09-04 /pmc/articles/PMC10476453/ /pubmed/37667349 http://dx.doi.org/10.1186/s12959-023-00532-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Kexin
Jiang, Yao
Zeng, Hesong
Zhu, Hongling
Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
title Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
title_full Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
title_fullStr Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
title_full_unstemmed Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
title_short Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
title_sort application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476453/
https://www.ncbi.nlm.nih.gov/pubmed/37667349
http://dx.doi.org/10.1186/s12959-023-00532-0
work_keys_str_mv AT zhangkexin applicationandriskpredictionofthrombolytictherapyincardiocerebrovasculardiseasesareview
AT jiangyao applicationandriskpredictionofthrombolytictherapyincardiocerebrovasculardiseasesareview
AT zenghesong applicationandriskpredictionofthrombolytictherapyincardiocerebrovasculardiseasesareview
AT zhuhongling applicationandriskpredictionofthrombolytictherapyincardiocerebrovasculardiseasesareview

Ejemplares similares